薬物代謝の遺伝子解析に用いるDNAチップシステムの開発に関する研究

1. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene

expression patterns with a complementary DNA microarray. Science 1995;270:467-470.

2. Watson A, Mazumder A, Stewart M, Balasubramanian S. Technology for microarray

analysis of gene expression. Curr Opin Biotechnol 1998;9:609-614.

3. Xiang CC, Chen Y. cDNA microarray technology and its applications. Biotechnol Adv

2000;18:35-46.

4. Stears RL, Martinsky T, Schena M. Trends in microarray analysis. Nat Med

2003;9:140-145.

5. Butte A. The use and analysis of microarray data. Nat Rev Drug Discov 2002;1:951960.

6 Govindarajan R, Duraiyan J, Kaliyappan K. Microarray and its applications. J Pharm

Bioallied Sci 2012;4:S310-S312.

7. Marquette CA, Lawrence I, Polychronakos C. Impedance based DNA chip for direct

Tm measurement. Talanta 2002;56:763-768.

8. Jo SB, Lee MW, Park SG, Suh JK. Fabrication and surface treatment of silicon mold

for polymer microarray. Surf Coat Technol 2004;188-189:452-458.

9. Bertone P, Snyder M. Advances in functional protein microarray technology. FEBS J

2005;272:5400-5411.

10. Liu CN, Toriello NM, Mathie RA. Multichannel PCR-CE microdevice for genetic

analysis. Anal Chem 2006;78:5474-5479.

11. He S, Song B, Li D, Zhu C, Qi W, Wen Y, Wang L, Song S, Fang H, Fan C. A graphene

nanoprobe for rapid, sensitive, and multicolor fluorescent DNA analysis. Adv Funct

Mater 2010;20:453-459.

81

12. Nunez R. DNA measurement and cell cycle analysis by flow cytometry. Curr Issues

Mol Biol 2001;3:67-70.

13. Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment.

N Eng J Med 2018;379:1754-1765.

14. Tegenfeldt JO, Prinz C, Cao H, Huang RL, Austin RH, Chou SY, Cox EC, Sturm JC.

Micro-and nanofluidics for DNA analysis. Anal Bioanal Chem 2004;378:1678-1692.

15. Sakata T, Kamahori M, Miyahara Y. DNA analysis chip based on field-effect

transistors. Jpn J Appl Phys 2005;44:2854-2859.

16. Panda S, Sato TK, Hampton GM, Hogenesch JB. An array of insights: application of

DNA chip technology in the study of cell biology. Trends Cell Biol 2003;13:151-156.

17. An HJ, Cho NH, Lee SY, Kim IH, Lee C. Correlation of cervical carcinoma and

precancerous lesions with human papillomavirus (HPV) genotypes detected with the

HPV DNA chip microarray method. Cancer 2003;97:1672-1680.

18. Dalstein V, Merlin S, Bali C, Saunier M. Analytical evaluation of the PapilloCheck

test, a new commercial DNA chip for detection and genotyping of human papillomavirus.

J Virol Methods 2009;156:77-83.

19. Nesvold H, Kristoffersen AB, Holst-Jensen A, Berdal KG. Design of a DNA chip for

detection of unknown genetically modified organisms (GMOs). Bioinformatics

2005;21:1917-1926.

20. Carinci F, Pezzetti F, Volinia S. Analysis of MG63 osteoblastic‐cell response to a

new nanoporous implant surface by means of a microarray technology. Clin Oral Implants

Res 2004;15:180-186.

82

21. Meng F, Hasan A, Babadaei MMN, Kani PH, Talaei AJ, Sharifi M, Cai T, Falahati M,

Cai Y. Polymeric-based microneedle arrays as potential platforms in the development of

drugs delivery systems. J Adv Res 2020;26:137-147.

22. Kolman CJ, Tuross N. Ancient DNA analysis of human populations. Am J Phys

Anthropol 2000;111:5-23.

23. Ricciardi S, Castagna R, Severino SM, Ferrante I. Surface functionalization by polyacrylic acid plasma-polymerized films for microarray DNA diagnostics. Surf Coat

Technol 2012;207:389-399.

24. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA,

Trent JM. Use of a cDNA microarray to analyse gene expression patterns in human cancer.

Nat Genet 1996;14:457-460.

25. Angenendt P. Progress in protein and antibody. Drug Discov Today 2005;10:503-511.

26. Barbulovic-Nad I, Lucente M, Sun Y. Bio-microarray fabrication techniques—a

review. Crit Rev Biotechnol 2006;26:237-259.

27. Pack SP, Kamisetty NK, Nonogawa M. Direct immobilization of DNA oligomers onto

the amine-functionalized glass surface for DNA microarray fabrication through the

activation-free reaction of oxanine. Nucleic Acids Res 2007;35:e110.

28. Moorcroft MJ, Meuleman WRA, Latham SG. In situ oligonucleotide synthesis on

poly (dimethylsiloxane): a flexible substrate for microarray fabrication. Nucleic Acids

Res 2005;33:8.

29. Lenigk R, Carles M, Ip NY, Sucher NJ. Surface characterization of a silicon-chipbased DNA microarray. Langmuir 2001;17:2497-2501.

30. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church

DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A,

83

Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C,

Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR,

Waggoner DJ, Watson MS, Martin CL, Ledbetter DH. Consensus statement:

chromosomal microarray is a first-tier clinical diagnostic test for individuals with

developmental disabilities or congenital anomalies. Am J Hum Genet 2010;86:749-764.

31. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS,

Hogervorst FBL, Hoogerbrugge N, Spurdle AB, Tavtigian S. Sequence variant

classification and reporting: recommendations for improving the interpretation of cancer

susceptibility genetic test results. Hum Mutat 2008;29:1282-1291.

32. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, Bottelli G,

Cerrone M, Leonardi S. Genetic testing in the long QT syndrome: development and

validation of an efficient approach to genotyping in clinical practice. JAMA

2005;294:2975-2980.

33. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ,

Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Marec HL, McKenna WJ,

Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP.

HRS/EHRA expert consensus statement on the state of genetic testing for the

channelopathies and cardiomyopathies: this document was developed as a partnership.

Heart Rhythm 2011;8:1308-1339.

34. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by

shrunken centroids of gene expression. PNAS 2002;99:6567-6572.

35. Ferrer M, Sanz ML, Sastre J, Bartra J, Cuvillo A, Montoro J, Jáuregui I, Dávila I,

Mullol J, Valero A. Molecular diagnosis in Allergology: application of the microarray

technique. J Investig Allergol Clin Immunol 2009;19:19-24.

84

36. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Béné MC, Vos JD,

Hernández JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ,

Rassenti LZ, Yeoh AE, Papenhausen, Liu W, Williams M, Foà R. Clinical utility of

microarray-based gene expression profiling in the diagnosis and subclassification of

leukemia: report from the International Microarray. J Clin Oncol 2010;28:2529-2537.

37. Cheung SW, Shaw CA, Yu W, Li J, Ou Z, Patel A, Yatsenko SA, Cooper ML, Furman

P, Stankiewicz P, Lupski JR, Chinault AC, Beaudet AL. Development and validation of a

CGH microarray for clinical cytogenetic diagnosis. Genet Med 2005;7:422-432.

38. Statnikov A, Aliferis CF, Tsamardinos I, Hardin D, Levy S. A comprehensive

evaluation of multicategory classification methods for microarray gene expression cancer

diagnosis. Bioinformatics 2005;21:631-643.

39. Stosic M, Levy B, Wapner R. The use of chromosomal microarray for prenatal

diagnosis. Obstet Gynecol Clin North Am 2016;45:55-68.

40. Shaffer LG, Dabell MP, Fisher AJ, Coppinger J, Bandholz AM, Ellison JW, Ravnan

JB, Torchia BS, Ballif BC, Rosenfeld JA. Experience with microarray-based comparative

genomic hybridization for prenatal diagnosis in over 5000 pregnancies. Prenat Diagn

2012;32:976-985.

41. Koch WH. Technology platfomrms for pharmacogenomic diagnostic assays. Nat Rev

Drug Discov 2004;3:749-761.

42. Takano M, Sugiyama T. UGT1A1 polymorphisms in cancer: impact on irinotecan

treatment. Pharmacogenomics Pers Med 2017;10:61-68.

43. Hazama S, Nagashima A, Kondo H, Yoshida S, Shimizu R, Araki A, Yoshino S,

Okayama N, Hinoda Y, Oka M. Phase I study of irinotecan and doxifluridine for

85

metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci

2010;101:722-727.

44. Takahashia K, Tanga M, Takai O, Okamura H. DNA preservation using diamond chips.

Diam Relat Mater 2003;12:572-576.

45. Tsunedomi R, Hazama S, Okayama N, Oka M, Nagano H. Rapid and sensitive

detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA

microarray. Cancer Sci 2017;108:1504-1509.

46. Hanaoka T, Takai O, Takahashi K, Tsugane S. Chip ligating human genomic DNA

serves as storage material and template for polymerase chain reaction. Biotechnol Lett

2003;25:509-512.

47. Tuoya, Hirayama K, Nagaoka T, Yu D, Fukuda T, Tada H, Yamada H, Seno M.

Identification of cell surface marker candidates on SV-T2 cells using DNA microarray on

DLC-coated glass. Biochem Biophys Res Commun 2005;334:263-268.

48. McQuain MK, Seale K, Peek J, Fisher TS, Levy S, Stremler MA, Haselton FR.

Chaotic mixer improves microarray hybridization. Anal Biochem 2004;325:215-226.

49. Zammatteo N, Jeanmart L, Hamels S, Courtois S, Louette P, Hevesi L, Remacle J.

Comparison between different strategies of covalent attachment of DNA to glass surfaces

to build DNA microarrays. Anal Biochem 2000;280:143-150.

50. Wong ELS, Chow E, Gooding JJ. DNA recognition interfaces: the influence of

interfacial design on the efficiency and kinetics of hybridization. Langmuir

2005;21:6957-6965.

51. Oh SJ, Cho SJ, Kim CO, Park JW. Characteristics of DNA microarrays fabricated on

various aminosilane layers. Langmuir 2002;18:1764-1769.

86

52. Li W, Ruan K. MicroRNA detection by microarray. Anal Bioanal Chem

2009;394:1117-1124.

53. Golden JP, Ligler FS. A comparison of imaging methods for use in an array biosensor.

Biosensors Bioelectron 2002;17:719-725.

54. Roy E, Voisin B, Gravel JF, Peytavi R, Boudreau D, Veres T. Microlens array

fabrication by enhanced thermal reflow process: towards efficient collection of

fluorescence light from microarrays. Microelectron Eng 2009;86:2255-2261.

55. Nagl S, Schaeferling M, Wolfbeis OS. Fluorescence analysis in microarray technology.

Microchim Acta 2005;151:1-21.

56. Ridder D, Linden CE, Schonewille T, Dik WA, Reinders MJT, Dongen JJM, Staal

FJT. Purity for clarity: the need for purification of tumor cells in DNA microarray studies.

Leukemia 2005;19:618-627.

57. Watson JD, Crick FHC. Molecular structure of nucleic acids. Nature 1953;171:737–

738.

58. Nei M. Molecular structure of nucleic acids: analysis of gene diversity in subdivided

populations. Proc Natl Acad Sci U S A 1973;70:3321-3323.

59. Dopazo J, Zanders E, Dragoni I, Amphlett G, Falciani F. Methods and approaches in

the analysis of gene expression data. Journal of Immunological Methods 2001;250:93112.

60. Mi H, Muruganujan A, Huang X, Ebert D, Mills C, Guo X Thomas PD. Protocol

update for large-scale genome and gene function analysis with the PANTHER

classification system. Nature Protocols 2019;14:703–721.

61. Siegrist M. The Influence of Trust and Perceptions of risks and benefits on the

acceptance of gene technology. Risk Analysis 2000; 20:195–203.

87

62. Ginzinger DG. Gene quantification using real-time quantitative PCR:An emerging

technology hits the mainstream. Experimental Hematology 2002;30:503–512.

63. Hodson R. Precision medicine. Nature 1953;171:49.

64. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med

2015;372:793-5.

65. König IR, Fuchs O, Hansen G, Mutius E, Kopp MV. What is precision medicine. Eur

Respir J 2017; 50:1-12.

66. Khoury MJ, Gwinn ML, Glasgow RE, Kramer BS. A Population approach to

precision medicine. Am J Prev Med 2012;42:639–645.

67. Hunasikatti M. Reinventing polysomnography in the age of precision medicine - Not

at the cost of discarding the hard data. Sleep Medicine Reviews 2020;54.

68. Mesko B. The role of artificial intelligence in precision medicine. Expert Review Of

Precision Medicine And Drug Development 2017;2:239–241.

69. Sun W, Lee J, Zhang S, Benyshek C, Dokmeci NR, Khademhosseini A. Engineering

Precision Medicine. Adv. Sci. 2019;6:1801039.

70. Kohane IS. Ten things we have to do to achieve precision medicine. Science

2015;349:37-38.

71. Denny JC, Collins FS. Precision medicine in 2030 seven ways to transform healthcare.

Cell 2021;184:1415-1419.

72. Wang Y, Sun S, Zhang Z, Shi D. Nanomaterials for cancer precision medicine. Adv

Mater 2018;30:1705660.

73. Reitz C. Toward precision medicine in Alzheimer’s disease. Ann Transl Med

2016;4:107.

88

74. Gavan SP, Thompson AJ, Payne K. The economic case for precision medicine. Expert

Review Of Precision Medicine And Drug Development 2018;3:1–9.

75. Politi K, Herbst RS. Lung cancer in the era of precision medicine. Clin Cancer Res

2015;21:2213-2220.

76. Tourneau CL, Borcoman E, Kamal M. Molecular profiling in precision medicine

oncology. Nat ure Medicine 2019;25:711–715.

77. Shin SH, Bode AM, Dong Z. Precision medicine the foundation of future cancer

therapeutics. npj Precision Oncology 2017;1:12.

78. El CG, Cornel MC, Borry P, et al. Whole-genome sequencing in health care. European

Journal of Human Genetics 2013;21:580–584.

79. Dewey FE, Grove ME, Pan C, et al. Clinical interpretation and implications of wholegenome sequencing. JAMA 2014;311:1035-1045.

80. Gudbjartsson DF, Helgason H, Stefansson K, et al. Large-scale whole-genome

sequencing of the Icelandic population. Nature Genetics 2015;47:435–444.

81. Turro E, Astle WJ, Ouwehand WH. Whole-genome sequencing of patients with rare

diseases in a national health system. Nature 2020;583:96–102.

82. Schwarz K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and wholegenome sequencing approaches cost-effective? A systematic review of the literature.

Genetics in Medicine 2018;20:1122–1130.

83. Tyler AD, Mataseje L, Urfano CJ, Schmidt L, Antonation KS, Mulvey MR, Corbett

CR. Evaluation of oxford nanopore’s MinION sequencing device for microbial whole

genome sequencing applications. Scientific Reports 2018; 8:10931.

84. Staaf J, Glodzik D, Bosch A, at al. Whole-genome sequencing of triple-negative

breast cancers in a population-based clinical study. Nature Medicine 2019;25:1526–1533.

89

85. Lionel AC, Costain G, Monfared N, at al. Improved diagnostic yield compared with

targeted gene sequencing panels suggests a role for whole-genome sequencing as a firsttier genetic test. Genet Med 2018;20:435-443.

86. Lippert C, Sabatini R, Maher MC, at al. Identification of individuals by trait prediction

using whole-genome sequencing data. PNAS 2017;114:10166-1017.

87. Ciriano IC, Koo JJ Lee, Xi R. Comprehensive analysis of chromothripsis in 2,658

human cancers using whole-genome sequencing. Nature Genetics 2020;52:331–341.

88. Spivak JL. Myeloproliferative neoplasms. N Engl J Med 2017;376:2168-2181.

89. Tefferi A, Pardanani A. Myeloproliferative neoplasms. JAMA Oncol 2015;1:97-105.

90. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and

management of myeloproliferative neoplasms. CA Cancer J Clin 2009;59:171-91.

91. Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on

myeloproliferative neoplasms. N Engl J Med 2015;372:601-612.

92. Grinfeld J, Nangalia J, Baxter J, et al. Classification and personalized prognosis in

myeloproliferative neoplasms. N Engl J Med 2018;379:1416-1430.

93. Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes.

Blood 2017;130:2475-2483.

94. Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms when, which agent,

and how. Blood 2014;124:3529-37.

95. Venugopal S, Mascarenhas J. Novel therapeutics in myeloproliferative neoplasms.

Journal of Hematology & Oncology 2020;13:162.

96. Marneth AE, Mullally A. The molecular genetics of myeloproliferative neoplasms.

Cold Spring Harb Perspect Med 2020;10:a034876.

90

97. Grinfeld J. Prognostic models in the myeloproliferative neoplasms. Blood Rev

2020;42:100713.

98. Lanktree MB, Chapman AB. New treatment paradigms for ADPKD moving towards

precision medicine. Nat Rev Nephrol 2017;13:750-768.

99. Gürsoy G, Bjornson R, Green ME, Gerstein M. Using blockchain to log genome

dataset access efficient storage and query. BMC Med Genomics 2020;13:78.

100. Ozercan HI, Ileri AM, Ayday E, Alkan C. Realizing the potential of blockchain

technologies in genomics. Genome Res 2018;28:1255–1263.

101. Racine V. Can blockchain solve the dilemma in the ethics of genomic biobanks.

Science and Engineering Ethics 2021;27:35.

102. Shabani M. Blockchain-based platforms for genomic data sharing a de-centralized

approach in response to the governance problems. Journal of the American Medical

Informatics Association 2019;26:76–80.

103. Hendricks-Sturrup RM, Lu CY. What motivates the sharing of consumer-generated

genomic information. SAGE Open Med 2020;8:2050312120915400.

104. Srivastava S, Singh SV, Singh RB, Shukla HK. Digital transformation of healthcare:

a blockchain study. International Journal of Innovative Science, Engineering &

Technology 2021;8:2348 – 7968.

105. Mohammadipanah F, Sajedi H. Potential of blockchain approach on development

and security of microbial databases. Biological Procedures Online 2021;23:3.

106. Abdu NAA, Wang Z. Blockchain for healthcare sector-analytical review. Mater Sci

Eng 2021;1110:012001.

107. Sawyer A. Who owns your DNA. Biotechniques 2021;71:355-357.

91

謝辞

本学位論文を終えるにあたり、本研究に御指導を賜りました筑波大学大

学院生命環境科学研究科生物機能科学専攻 深水昭吉教授に深甚なる謝意を表

します。また、本研究にあたりましてご指導頂きました山口大学大学院医学系研

究科 消化器・腫瘍外科学講座 永野浩昭教授と山口大学医学部 先端がん治療開

発学 硲彰一教授、山口大学 医学部附属病院 消化器・腫瘍外科学 恒富亮一講師

に心より感謝いたします。

92

...